Brand Navigation Banner

Treat with foresight
mCNV

mCNV

Strong, rapid, and sustained visual

gains over 48 weeks1

MOST VISUAL GAINS WERE ACHIEVED WITH 1 OR 2 INJECTIONS1

EYLEA®-treated patients had a mean gain of +12.1 letters and 39% gained ≥3 lines at Week 24,increasing to +13.5 letters and 50% with ≥3 lines gained at Week 481

WEEK 48

MEAN GAIN
MEAN CHANGE

Mean change in BCVA through Week 1001

MEAN CHANGE

EYLEA® 2 mg administered at baseline and monthly up to Week 44 if mCNV persisted or recurred; n=90.

Sham injection administered at baseline up to Week 20 regardless of whether re-treatment criteria were fulfilled or not, followed by EYLEA® 2 mg at Week 24 and monthly if disease persisted/recurred up to Week 44; n=31.

  • mCNV lesion size was reduced by >50% from baseline to Week 24 in the early EYLEA® treatment group1
  • Lesion size almost doubled in the delayed treatment group1
  • mCNV leakage was resolved by Week 48 in 86% of early EYLEA®-treated patients vs. 67% in the delayed treatment group1

DOSING

DOSING

DOSING

Pro-active dosing options across indications1

Read more
image

MOA

MOA

MOA

Unique multi-targeted trap mechanism1,4

Read more
image
Pre-Filled Syringe Pre-Filled Syringe

INTRODUCING THE NEW EYLEA® PRE-FILLED SYRINGE

WHAT'S INSIDE MAKES THE DIFFERENCE

 

Syringe cap with a simple twist mechanism, for controlled opening1

LEARN MORE

BCVA, best-corrected visual acuity; mCNV, myopic choroidal neovascularization; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; RCT, randomized controlled trial; VA, visual acuity

References:

  • Ikuno Y, Ohno-Matsui K, Wong TY et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR study. Ophthalmology. 2015;122(6):1220–1227. Return to content
  • EYLEA® (aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG. Return to content